Mail-Order Mifepristone Effective, Feasible for Medication Abortion
By Elana Gotkine HealthDay Reporter
MONDAY, May 13, 2024 -- Mail-order pharmacy dispensing of mifepristone for medication abortion is effective, acceptable, and feasible, according to a study published online May 13 in JAMA Internal Medicine.
Daniel Grossman, M.D., from the University of California, San Francisco, and colleagues estimated the effectiveness, acceptability, and feasibility of dispensing mifepristone for medication abortion using a mail-order pharmacy in a prospective cohort study including 11 clinics in seven states. Eligible participants were seeking medication abortion at 63 or fewer days of gestation. After in-person screening assessing eligibility for medication abortion, mifepristone and misoprostol were prescribed using a mail-order pharmacy.
Clinical outcome information was obtained and analyzed from 510 abortions among 506 participants. Medications were received within three days for 436 (85.5 percent) of these abortions. In 499 cases (97.8 percent), complete abortion occurred after medication use. The researchers found that 24 adverse events (4.7 percent) occurred for which care was sought for medication abortion symptoms; serious adverse events requiring hospitalization were experienced by three patients (0.6 percent), but no adverse events were associated with mail-order dispensing. Overall, 90.4 percent of 477 participants indicated that they would use mail-order dispensing again for abortion care and 91.2 percent reported satisfaction with medication abortion. Findings were similar to those of studies reporting in-person dispensing.
"This study adds to the substantial body of evidence supporting the U.S. Food and Drug Administration's decision to remove the in-person dispensing requirement for mifepristone," the authors write.
One author served as an expert witness in cases challenging abortion restrictions, including restrictions on telemedicine.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Dobbs Decision Has Negatively Impacted Access to OB/GYN Practitioners
FRIDAY, March 14, 2025 -- The Dobbs v Jackson Women's Health Organization (Dobbs) decision was associated with a moderate but significant relative reduction in obstetrics and...
States That Adopted Abortion Bans Have Higher Infant Mortality
TUESDAY, Feb. 25, 2025 -- U.S. states that adopted abortion bans have higher-than-expected infant mortality and higher fertility rates than expected, according to two studies...
Thousands of People Are Leaving Abortion-Ban States, Study Shows
FRIDAY, Jan. 10, 2025 -- States with strict abortion bans are losing residents, particularly younger people, which could have long-term economic implications. In the wake of the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.